Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?

Daniel A. Goldstein, MD and Bishal Gyawali, MD, VIVIO Clinical Advisory Board

Journal of Clinical Oncology, 03/24/2023
The benefit of any treatment for any disease should be judged by whether it improves either survival or its quality. For adjuvant treatment of cancer, effects on overall survival (OS) are paramount: Patients and their oncologists are willing to accept substantial toxicity and short-term deficits in quality of life, if long-term survival can be improved. Assessment of the validity of randomized controlled trials (RCTs) evaluating adjuvant therapy requires that several questions about trial design and analysis be addressed.

Read the full article at: https://ascopubs.org/doi/full/10.1200/JCO.23.00280